Pharmaceuticals: World Market Overview (Market size, Segmentation and Trends Analysis)

TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Introduction 19
What is this report about? 19
Who is the target reader? 19
How to use this report 19
Definitions 19
Global Pharmaceuticals 20
Market Overview 20
Market Data 21
Market Segmentation 22
Market outlook 24
Five forces analysis 25
Pharmaceuticals in Asia-Pacific 33
Market Overview 33
Market Data 34
Market Segmentation 35
Market outlook 37
Five forces analysis 38
Pharmaceuticals in Europe 46
Market Overview 46
Market Data 47
Market Segmentation 48
Market outlook 50
Five forces analysis 51
Pharmaceuticals in France 59
Market Overview 59
Market Data 60
Market Segmentation 61
Market outlook 63
Five forces analysis 64
Macroeconomic indicators 72
Pharmaceuticals in Germany 74
Market Overview 74
Market Data 75
Market Segmentation 76
Market outlook 78
Five forces analysis 79
Macroeconomic indicators 87
Pharmaceuticals in Italy 89
Market Overview 89
Market Data 90
Market Segmentation 91
Market outlook 93
Five forces analysis 94
Macroeconomic indicators 102
Pharmaceuticals in Japan 104
Market Overview 104
Market Data 105
Market Segmentation 106
Market outlook 108
Five forces analysis 109
Macroeconomic indicators 117
Pharmaceuticals in Belgium 119
Market Overview 119
Market Data 120
Market Segmentation 121
Market outlook 123
Five forces analysis 124
Macroeconomic indicators 132
Pharmaceuticals in Canada 134
Market Overview 134
Market Data 135
Market Segmentation 136
Market outlook 138
Five forces analysis 139
Macroeconomic indicators 147
Pharmaceuticals in China 149
Market Overview 149
Market Data 150
Market Segmentation 151
Market outlook 153
Five forces analysis 154
Macroeconomic indicators 162
Pharmaceuticals in The Netherlands 164
Market Overview 164
Market Data 165
Market Segmentation 166
Market outlook 168
Five forces analysis 169
Macroeconomic indicators 177
Pharmaceuticals in Spain 179
Market Overview 179
Market Data 180
Market Segmentation 181
Market outlook 183
Five forces analysis 184
Macroeconomic indicators 192
Pharmaceuticals in The United Kingdom 194
Market Overview 194
Market Data 195
Market Segmentation 196
Market outlook 198
Five forces analysis 199
Macroeconomic indicators 207
Pharmaceuticals in The United States 209
Market Overview 209
Market Data 210
Market Segmentation 211
Market outlook 213
Five forces analysis 214
Macroeconomic indicators 222
Company Profiles 224
Leading companies 224
Appendix 267
Methodology 267

LIST OF TABLES
Table 1: Global pharmaceuticals market value: $ billion, 2007–11 21
Table 2: Global pharmaceuticals market geography segmentation: $ billion, 2011 22
Table 3: Global pharmaceuticals market share: % share, by value, 2011 23
Table 4: Global pharmaceuticals market value forecast: $ billion, 2011–16 24
Table 5: Asia-Pacific pharmaceuticals market value: $ billion, 2007–11 34
Table 6: Asia–Pacific pharmaceuticals market geography segmentation: $ billion, 2011 35
Table 7: Asia-Pacific pharmaceuticals market share: % share, by value, 2011 36
Table 8: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2011–16 37
Table 9: Europe pharmaceuticals market value: $ billion, 2007–11 47
Table 10: Europe pharmaceuticals market geography segmentation: $ billion, 2011 48
Table 11: Europe pharmaceuticals market share: % share, by value, 2011 49
Table 12: Europe pharmaceuticals market value forecast: $ billion, 2011–16 50
Table 13: France pharmaceuticals market value: $ billion, 2007–11 60
Table 14: France pharmaceuticals market geography segmentation: $ billion, 2011 61
Table 15: France pharmaceuticals market share: % share, by value, 2011 62
Table 16: France pharmaceuticals market value forecast: $ billion, 2011–16 63
Table 17: France size of population (million), 2007–11 72
Table 18: France gdp (constant 2000 prices, $ billion), 2007–11 72
Table 19: France gdp (current prices, $ billion), 2007–11 72
Table 20: France inflation, 2007–11 73
Table 21: France consumer price index (absolute), 2007–11 73
Table 22: France exchange rate, 2007–11 73
Table 23: Germany pharmaceuticals market value: $ billion, 2007–11 75
Table 24: Germany pharmaceuticals market geography segmentation: $ billion, 2011 76
Table 25: Germany pharmaceuticals market share: % share, by value, 2011 77
Table 26: Germany pharmaceuticals market value forecast: $ billion, 2011–16 78
Table 27: Germany size of population (million), 2007–11 87
Table 28: Germany gdp (constant 2000 prices, $ billion), 2007–11 87
Table 29: Germany gdp (current prices, $ billion), 2007–11 87
Table 30: Germany inflation, 2007–11 88
Table 31: Germany consumer price index (absolute), 2007–11 88
Table 32: Germany exchange rate, 2007–11 88
Table 33: Italy pharmaceuticals market value: $ billion, 2007–11 90
Table 34: Italy pharmaceuticals market geography segmentation: $ billion, 2011 91
Table 35: Italy pharmaceuticals market share: % share, by value, 2011 92
Table 36: Italy pharmaceuticals market value forecast: $ billion, 2011–16 93
Table 37: Italy size of population (million), 2007–11 102
Table 38: Italy gdp (constant 2000 prices, $ billion), 2007–11 102
Table 39: Italy gdp (current prices, $ billion), 2007–11 102
Table 40: Italy inflation, 2007–11 103
Table 41: Italy consumer price index (absolute), 2007–11 103
Table 42: Italy exchange rate, 2007–11 103
Table 43: Japan pharmaceuticals market value: $ billion, 2007–11 105
Table 44: Japan pharmaceuticals market geography segmentation: $ billion, 2011 106
Table 45: Japan pharmaceuticals market share: % share, by value, 2011 107
Table 46: Japan pharmaceuticals market value forecast: $ billion, 2011–16 108
Table 47: Japan size of population (million), 2007–11 117
Table 48: Japan gdp (constant 2000 prices, $ billion), 2007–11 117
Table 49: Japan gdp (current prices, $ billion), 2007–11 117
Table 50: Japan inflation, 2007–11 118
Table 51: Japan consumer price index (absolute), 2007–11 118
Table 52: Japan exchange rate, 2007–11 118
Table 53: Belgium pharmaceuticals market value: $ billion, 2007–11 120
Table 54: Belgium pharmaceuticals market geography segmentation: $ billion, 2011 121
Table 55: Belgium pharmaceuticals market share: % share, by value, 2011 122
Table 56: Belgium pharmaceuticals market value forecast: $ billion, 2011–16 123
Table 57: Belgium size of population (million), 2007–11 132
Table 58: Belgium gdp (constant 2000 prices, $ billion), 2007–11 132
Table 59: Belgium gdp (current prices, $ billion), 2007–11 132
Table 60: Belgium inflation, 2007–11 133
Table 61: Belgium consumer price index (absolute), 2007–11 133
Table 62: Belgium exchange rate, 2007–11 133
Table 63: Canada pharmaceuticals market value: $ billion, 2007–11 135
Table 64: Canada pharmaceuticals market geography segmentation: $ billion, 2011 136
Table 65: Canada pharmaceuticals market share: % share, by value, 2011 137
Table 66: Canada pharmaceuticals market value forecast: $ billion, 2011–16 138
Table 67: Canada size of population (million), 2007–11 147
Table 68: Canada gdp (constant 2000 prices, $ billion), 2007–11 147
Table 69: Canada gdp (current prices, $ billion), 2007–11 147
Table 70: Canada inflation, 2007–11 148
Table 71: Canada consumer price index (absolute), 2007–11 148
Table 72: Canada exchange rate, 2007–11 148
Table 73: China pharmaceuticals market value: $ billion, 2007–11 150
Table 74: China pharmaceuticals market geography segmentation: $ billion, 2011 151
Table 75: China pharmaceuticals market share: % share, by value, 2011 152
Table 76: China pharmaceuticals market value forecast: $ billion, 2011–16 153
Table 77: China size of population (million), 2007–11 162
Table 78: China gdp (constant 2000 prices, $ billion), 2007–11 162
Table 79: China gdp (current prices, $ billion), 2007–11 162
Table 80: China inflation, 2007–11 163
Table 81: China consumer price index (absolute), 2007–11 163
Table 82: China exchange rate, 2007–11 163
Table 83: Netherlands pharmaceuticals market value: $ million, 2007–11 165
Table 84: Netherlands pharmaceuticals market geography segmentation: $ million, 2011 166
Table 85: Netherlands pharmaceuticals market share: % share, by value, 2011 167
Table 86: Netherlands pharmaceuticals market value forecast: $ million, 2011–16 168
Table 87: Netherlands size of population (million), 2007–11 177
Table 88: Netherlands gdp (constant 2000 prices, $ billion), 2007–11 177
Table 89: Netherlands gdp (current prices, $ billion), 2007–11 177
Table 90: Netherlands inflation, 2007–11 178
Table 91: Netherlands consumer price index (absolute), 2007–11 178
Table 92: Netherlands exchange rate, 2007–11 178
Table 93: Spain pharmaceuticals market value: $ billion, 2007–11 180
Table 94: Spain pharmaceuticals market geography segmentation: $ billion, 2011 181
Table 95: Spain pharmaceuticals market share: % share, by value, 2011 182
Table 96: Spain pharmaceuticals market value forecast: $ billion, 2011–16 183
Table 97: Spain size of population (million), 2007–11 192
Table 98: Spain gdp (constant 2000 prices, $ billion), 2007–11 192
Table 99: Spain gdp (current prices, $ billion), 2007–11 192
Table 100: Spain inflation, 2007–11 193
Table 101: Spain consumer price index (absolute), 2007–11 193
Table 102: Spain exchange rate, 2007–11 193
Table 103: United Kingdom pharmaceuticals market value: $ billion, 2007–11 195
Table 104: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2011 196
Table 105: United Kingdom pharmaceuticals market share: % share, by value, 2011 197
Table 106: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16 198
Table 107: United Kingdom size of population (million), 2007–11 207
Table 108: United Kingdom gdp (constant 2000 prices, $ billion), 2007–11 207
Table 109: United Kingdom gdp (current prices, $ billion), 2007–11 207
Table 110: United Kingdom inflation, 2007–11 208
Table 111: United Kingdom consumer price index (absolute), 2007–11 208
Table 112: United Kingdom exchange rate, 2007–11 208
Table 113: United States pharmaceuticals market value: $ billion, 2007–11 210
Table 114: United States pharmaceuticals market geography segmentation: $ billion, 2011 211
Table 115: United States pharmaceuticals market share: % share, by value, 2011 212
Table 116: United States pharmaceuticals market value forecast: $ billion, 2011–16 213
Table 117: United States size of population (million), 2007–11 222
Table 118: United States gdp (constant 2000 prices, $ billion), 2007–11 222
Table 119: United States gdp (current prices, $ billion), 2007–11 222
Table 120: United States inflation, 2007–11 223
Table 121: United States consumer price index (absolute), 2007–11 223
Table 122: United States exchange rate, 2007–11 223
Table 123: Pfizer Inc.: key facts 224
Table 124: Pfizer Inc.: key financials ($) 225
Table 125: Pfizer Inc.: key financial ratios 225
Table 126: GlaxoSmithKline Plc: key facts 227
Table 127: GlaxoSmithKline Plc: key financials ($) 228
Table 128: GlaxoSmithKline Plc: key financials (£) 229
Table 129: GlaxoSmithKline Plc: key financial ratios 229
Table 130: AstraZeneca PLC: key facts 231
Table 131: AstraZeneca PLC: key financials ($) 232
Table 132: AstraZeneca PLC: key financial ratios 233
Table 133: Merck & Co., Inc.: key facts 235
Table 134: Merck & Co., Inc.: key financials ($) 236
Table 135: Merck & Co., Inc.: key financial ratios 236
Table 136: Daiichi Sankyo Co., Ltd.: key facts 238
Table 137: Daiichi Sankyo Co., Ltd.: key financials ($) 239
Table 138: Daiichi Sankyo Co., Ltd.: key financials (¥) 239
Table 139: Daiichi Sankyo Co., Ltd.: key financial ratios 239
Table 140: Astellas Pharma Inc.: key facts 241
Table 141: Astellas Pharma Inc.: key financials ($) 242
Table 142: Astellas Pharma Inc.: key financials (¥) 242
Table 143: Astellas Pharma Inc.: key financial ratios 242
Table 144: Novartis AG: key facts 244
Table 145: Novartis AG: key financials ($) 245
Table 146: Novartis AG: key financial ratios 245
Table 147: Chiesi Farmaceutici S.P.A.: key facts 247
Table 148: Menarini Group, The: key facts 249
Table 149: Takeda Pharmaceutical Company Limited: key facts 250
Table 150: Takeda Pharmaceutical Company Limited: key financials ($) 251
Table 151: Takeda Pharmaceutical Company Limited: key financials (¥) 251
Table 152: Takeda Pharmaceutical Company Limited: key financial ratios 251
Table 153: Mitsubishi Tanabe Pharma Corporation: key facts 253
Table 154: Mitsubishi Tanabe Pharma Corporation: key financials ($) 254
Table 155: Mitsubishi Tanabe Pharma Corporation: key financials (¥) 254
Table 156: Mitsubishi Tanabe Pharma Corporation: key financial ratios 254
Table 157: Johnson & Johnson: key facts 256
Table 158: Johnson & Johnson: key financials ($) 257
Table 159: Johnson & Johnson: key financial ratios 257
Table 160: Jiangsu Yangtze River Pharmaceutical Group Company Ltd.: key facts 259
Table 161: Almirall S.A.: key facts 260
Table 162: Almirall S.A.: key financials ($) 260
Table 163: Almirall S.A.: key financials (€) 261
Table 164: Almirall S.A.: key financial ratios 261
Table 165: Sanofi: key facts 263
Table 166: Sanofi: key financials ($) 264
Table 167: Sanofi: key financials (€) 264
Table 168: Sanofi: key financial ratios 265

LIST OF FIGURES
Figure 1: Global pharmaceuticals market value: $ billion, 2007–11 25
Figure 2: Global pharmaceuticals market geography segmentation: % share, by value, 2011 26
Figure 3: Global pharmaceuticals market share: % share, by value, 2011 27
Figure 4: Global pharmaceuticals market value forecast: $ billion, 2011–16 28
Figure 5: Forces driving competition in the global pharmaceuticals market, 2011 29
Figure 6: Drivers of buyer power in the global pharmaceuticals market, 2011 30
Figure 7: Drivers of supplier power in the global pharmaceuticals market, 2011 32
Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals market, 2011 33
Figure 9: Factors influencing the threat of substitutes in the global pharmaceuticals market, 2011 35
Figure 10: Drivers of degree of rivalry in the global pharmaceuticals market, 2011 36
Figure 11: Asia-Pacific pharmaceuticals market value: $ billion, 2007–11 38
Figure 12: Asia–Pacific pharmaceuticals market geography segmentation: % share, by value, 2011 39
Figure 13: Asia-Pacific pharmaceuticals market share: % share, by value, 2011 40
Figure 14: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2011–16 41
Figure 15: Forces driving competition in the pharmaceuticals market in Asia-Pacific, 2011 42
Figure 16: Drivers of buyer power in the pharmaceuticals market in Asia-Pacific, 2011 43
Figure 17: Drivers of supplier power in the pharmaceuticals market in Asia-Pacific, 2011 45
Figure 18: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Asia-Pacific, 2011 46
Figure 19: Factors influencing the threat of substitutes in the pharmaceuticals market in Asia-Pacific, 2011 48
Figure 20: Drivers of degree of rivalry in the pharmaceuticals market in Asia-Pacific, 2011 49
Figure 21: Europe pharmaceuticals market value: $ billion, 2007–11 51
Figure 22: Europe pharmaceuticals market geography segmentation: % share, by value, 2011 52
Figure 23: Europe pharmaceuticals market share: % share, by value, 2011 53
Figure 24: Europe pharmaceuticals market value forecast: $ billion, 2011–16 54
Figure 25: Forces driving competition in the pharmaceuticals market in Europe, 2011 55
Figure 26: Drivers of buyer power in the pharmaceuticals market in Europe, 2011 56
Figure 27: Drivers of supplier power in the pharmaceuticals market in Europe, 2011 58
Figure 28: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Europe, 2011 59
Figure 29: Factors influencing the threat of substitutes in the pharmaceuticals market in Europe, 2011 61
Figure 30: Drivers of degree of rivalry in the pharmaceuticals market in Europe, 2011 62
Figure 31: France pharmaceuticals market value: $ billion, 2007–11 64
Figure 32: France pharmaceuticals market geography segmentation: % share, by value, 2011 65
Figure 33: France pharmaceuticals market share: % share, by value, 2011 66
Figure 34: France pharmaceuticals market value forecast: $ billion, 2011–16 67
Figure 35: Forces driving competition in the pharmaceuticals market in France, 2011 68
Figure 36: Drivers of buyer power in the pharmaceuticals market in France, 2011 69
Figure 37: Drivers of supplier power in the pharmaceuticals market in France, 2011 71
Figure 38: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2011 72
Figure 39: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2011 74
Figure 40: Drivers of degree of rivalry in the pharmaceuticals market in France, 2011 75
Figure 41: Germany pharmaceuticals market value: $ billion, 2007–11 79
Figure 42: Germany pharmaceuticals market geography segmentation: % share, by value, 2011 80
Figure 43: Germany pharmaceuticals market share: % share, by value, 2011 81
Figure 44: Germany pharmaceuticals market value forecast: $ billion, 2011–16 82
Figure 45: Forces driving competition in the pharmaceuticals market in Germany, 2011 83
Figure 46: Drivers of buyer power in the pharmaceuticals market in Germany, 2011 84
Figure 47: Drivers of supplier power in the pharmaceuticals market in Germany, 2011 86
Figure 48: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2011 87
Figure 49: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2011 89
Figure 50: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2011 90
Figure 51: Italy pharmaceuticals market value: $ billion, 2007–11 94
Figure 52: Italy pharmaceuticals market geography segmentation: % share, by value, 2011 95
Figure 53: Italy pharmaceuticals market share: % share, by value, 2011 96
Figure 54: Italy pharmaceuticals market value forecast: $ billion, 2011–16 97
Figure 55: Forces driving competition in the pharmaceuticals market in Italy, 2011 98
Figure 56: Drivers of buyer power in the pharmaceuticals market in Italy, 2011 99
Figure 57: Drivers of supplier power in the pharmaceuticals market in Italy, 2011 101
Figure 58: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2011 102
Figure 59: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2011 104
Figure 60: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2011 105
Figure 61: Japan pharmaceuticals market value: $ billion, 2007–11 109
Figure 62: Japan pharmaceuticals market geography segmentation: % share, by value, 2011 110
Figure 63: Japan pharmaceuticals market share: % share, by value, 2011 111
Figure 64: Japan pharmaceuticals market value forecast: $ billion, 2011–16 112
Figure 65: Forces driving competition in the pharmaceuticals market in Japan, 2011 113
Figure 66: Drivers of buyer power in the pharmaceuticals market in Japan, 2011 114
Figure 67: Drivers of supplier power in the pharmaceuticals market in Japan, 2011 116
Figure 68: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2011 117
Figure 69: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2011 119
Figure 70: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2011 120
Figure 71: Belgium pharmaceuticals market value: $ billion, 2007–11 124
Figure 72: Belgium pharmaceuticals market geography segmentation: % share, by value, 2011 125
Figure 73: Belgium pharmaceuticals market share: % share, by value, 2011 126
Figure 74: Belgium pharmaceuticals market value forecast: $ billion, 2011–16 127
Figure 75: Forces driving competition in the pharmaceuticals market in Belgium, 2011 128
Figure 76: Drivers of buyer power in the pharmaceuticals market in Belgium, 2011 129
Figure 77: Drivers of supplier power in the pharmaceuticals market in Belgium, 2011 131
Figure 78: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Belgium, 2011 132
Figure 79: Factors influencing the threat of substitutes in the pharmaceuticals market in Belgium, 2011 134
Figure 80: Drivers of degree of rivalry in the pharmaceuticals market in Belgium, 2011 135
Figure 81: Canada pharmaceuticals market value: $ billion, 2007–11 139
Figure 82: Canada pharmaceuticals market geography segmentation: % share, by value, 2011 140
Figure 83: Canada pharmaceuticals market share: % share, by value, 2011 141
Figure 84: Canada pharmaceuticals market value forecast: $ billion, 2011–16 142
Figure 85: Forces driving competition in the pharmaceuticals market in Canada, 2011 143
Figure 86: Drivers of buyer power in the pharmaceuticals market in Canada, 2011 144
Figure 87: Drivers of supplier power in the pharmaceuticals market in Canada, 2011 146
Figure 88: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2011 147
Figure 89: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2011 149
Figure 90: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2011 150
Figure 91: China pharmaceuticals market value: $ billion, 2007–11 154
Figure 92: China pharmaceuticals market geography segmentation: % share, by value, 2011 155
Figure 93: China pharmaceuticals market share: % share, by value, 2011 156
Figure 94: China pharmaceuticals market value forecast: $ billion, 2011–16 157
Figure 95: Forces driving competition in the pharmaceuticals market in China, 2011 158
Figure 96: Drivers of buyer power in the pharmaceuticals market in China, 2011 159
Figure 97: Drivers of supplier power in the pharmaceuticals market in China, 2011 161
Figure 98: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2011 162
Figure 99: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2011 164
Figure 100: Drivers of degree of rivalry in the pharmaceuticals market in China, 2011 165
Figure 101: Netherlands pharmaceuticals market value: $ million, 2007–11 169
Figure 102: Netherlands pharmaceuticals market geography segmentation: % share, by value, 2011 170
Figure 103: Netherlands pharmaceuticals market share: % share, by value, 2011 171
Figure 104: Netherlands pharmaceuticals market value forecast: $ million, 2011–16 172
Figure 105: Forces driving competition in the pharmaceuticals market in the Netherlands, 2011 173
Figure 106: Drivers of buyer power in the pharmaceuticals market in the Netherlands, 2011 174
Figure 107: Drivers of supplier power in the pharmaceuticals market in the Netherlands, 2011 176
Figure 108: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the Netherlands, 2011 177
Figure 109: Factors influencing the threat of substitutes in the pharmaceuticals market in the Netherlands, 2011 179
Figure 110: Drivers of degree of rivalry in the pharmaceuticals market in the Netherlands, 2011 180
Figure 111: Spain pharmaceuticals market value: $ billion, 2007–11 184
Figure 112: Spain pharmaceuticals market geography segmentation: % share, by value, 2011 185
Figure 113: Spain pharmaceuticals market share: % share, by value, 2011 186
Figure 114: Spain pharmaceuticals market value forecast: $ billion, 2011–16 187
Figure 115: Forces driving competition in the pharmaceuticals market in Spain, 2011 188
Figure 116: Drivers of buyer power in the pharmaceuticals market in Spain, 2011 189
Figure 117: Drivers of supplier power in the pharmaceuticals market in Spain, 2011 191
Figure 118: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Spain, 2011 192
Figure 119: Factors influencing the threat of substitutes in the pharmaceuticals market in Spain, 2011 194
Figure 120: Drivers of degree of rivalry in the pharmaceuticals market in Spain, 2011 195
Figure 121: United Kingdom pharmaceuticals market value: $ billion, 2007–11 199
Figure 122: United Kingdom pharmaceuticals market geography segmentation: % share, by value, 2011 200
Figure 123: United Kingdom pharmaceuticals market share: % share, by value, 2011 201
Figure 124: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16 202
Figure 125: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2011 203
Figure 126: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2011 204
Figure 127: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2011 206
Figure 128: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2011 207
Figure 129: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2011 209
Figure 130: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2011 210
Figure 131: United States pharmaceuticals market value: $ billion, 2007–11 214
Figure 132: United States pharmaceuticals market geography segmentation: % share, by value, 2011 215
Figure 133: United States pharmaceuticals market share: % share, by value, 2011 216
Figure 134: United States pharmaceuticals market value forecast: $ billion, 2011–16 217
Figure 135: Forces driving competition in the pharmaceuticals market in the United States, 2011 218
Figure 136: Drivers of buyer power in the pharmaceuticals market in the United States, 2011 219
Figure 137: Drivers of supplier power in the pharmaceuticals market in the United States, 2011 221
Figure 138: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2011 222
Figure 139: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2011 224
Figure 140: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2011 225
Figure 141: Pfizer Inc.: revenues & profitability 230
Figure 142: Pfizer Inc.: assets & liabilities 230
Figure 143: GlaxoSmithKline Plc: revenues & profitability 233
Figure 144: GlaxoSmithKline Plc: assets & liabilities 234
Figure 145: AstraZeneca PLC: revenues & profitability 237
Figure 146: AstraZeneca PLC: assets & liabilities 238
Figure 147: Merck & Co., Inc.: revenues & profitability 240
Figure 148: Merck & Co., Inc.: assets & liabilities 241
Figure 149: Daiichi Sankyo Co., Ltd.: revenues & profitability 244
Figure 150: Daiichi Sankyo Co., Ltd.: assets & liabilities 244
Figure 151: Astellas Pharma Inc.: revenues & profitability 247
Figure 152: Astellas Pharma Inc.: assets & liabilities 247
Figure 153: Novartis AG: revenues & profitability 250
Figure 154: Novartis AG: assets & liabilities 250
Figure 155: Takeda Pharmaceutical Company Limited: revenues & profitability 256
Figure 156: Takeda Pharmaceutical Company Limited: assets & liabilities 256
Figure 157: Mitsubishi Tanabe Pharma Corporation: revenues & profitability 259
Figure 158: Mitsubishi Tanabe Pharma Corporation: assets & liabilities 259
Figure 159: Johnson & Johnson: revenues & profitability 261
Figure 160: Johnson & Johnson: assets & liabilities 262
Figure 161: Almirall S.A.: revenues & profitability 265
Figure 162: Almirall S.A.: assets & liabilities 266
Figure 163: Sanofi: revenues & profitability 269
Figure 164: Sanofi: assets & liabilities 270

Pharmaceutical in China